

Arthritis drug used to limit antibiotics in blood cancer patients

May 12 2022, by Lee Gaskin



Anakinra mitigates melphalan-induced mucosal barrier injury and clinical manifestations of gut toxicity. (A) Mucosal barrier injury defined by plasma citrulline showed a significant decrease in MEL + ANA at D + 2 and D + 4 compared to melphalan only. (B–C) Anakinra prevented melphalan-induced weight loss and food intake (D–E). Data presented as mean \pm SEM. N = 8/group, all analyzed longitudinally using a mixed-effects model with Geisser-Greenhouse correction, with the exception of panel (E) which used a one-way ANOVA with Tukey's post-hoc. Credit: *Scientific Reports* (2022). DOI: 10.1038/s41598-022-10700-3



Researchers from the University of Adelaide and the Radboud University Medical Centre in the Netherlands have repurposed an arthritis drug to restrict the use of antibiotics in the treatment of side effects caused by blood cancer, including leukemia, lymphoma and myeloma.

Anakinra—a <u>biologic drug</u> that helps to decrease inflammation in rheumatoid arthritis and other <u>inflammatory diseases</u>—was found to have strengthened the gut lining and inhibited inflammation in rodents that were treated with chemotherapy.

This minimizes the spread of bacteria from the gut to the <u>blood stream</u>, which is a common cause of infection and can be serious for people with weakened immune systems as a result of chemotherapy or other cancer treatments.

Lead author, University of Adelaide cancer research fellow, Dr. Hannah Wardill, said the results had the potential to be an important breakthrough given the risks of developing a tolerance to antibiotics.

"We were able to show in a <u>rodent model</u> that the drug Anakinra improved the integrity of the <u>gut lining</u>," Dr. Wardill said.

"Antibiotics are the cornerstone of infection control in people with <u>blood</u> <u>cancer</u>, but they aren't without their challenges.

"Excessive antibiotic use not only contributes to the development of antibiotic resistance, but also increases the risk of chronic complications, especially in people undergoing stem cell transplantation."

About 1.24 million blood cancer cases occur worldwide annually, while about 18,000 Australians were newly diagnosed last year. Blood cancers—such as leukemia, lymphoma and myeloma—have increased



by 40 percent in the past decade.

Senior author and consultant hematologist at Radboud University Medical Centre, Professor Nicole Blijlevens, said a greater understanding of where infections originated led to finding alternative solutions to controlling bacteria.

"While we used to think infections predominantly came from external sources like hospital surfaces and equipment, we now know that they mainly come from inside the person's gut," Professor Blijlevens said. "This has refocused our attention to how we can prevent these bacteria from moving from the gut to the blood.

"We showed that this drug—which is usually used to control <u>rheumatoid</u> <u>arthritis</u>—was not associated with any adverse events in people undergoing high dose chemotherapy.

"For decades, we have relied on antibiotics to prevent infection, but this new work suggests there may be alternatives to minimize our reliance on antibiotics. We must find ways to restrict antibiotic use, especially in cancer care, but we must do this cautiously and based on the right evidence."

Anakinra has been approved for use in Australia and the Netherlands for arthritis, and is currently under investigation in the Netherlands for use in cancer care.

The full study has been published in Scientific Reports.

More information: H. R. Wardill et al, Supporting the gastrointestinal microenvironment during high-dose chemotherapy and stem cell transplantation by inhibiting IL-1 signaling with anakinra, *Scientific Reports* (2022). DOI: 10.1038/s41598-022-10700-3



Provided by University of Adelaide

Citation: Arthritis drug used to limit antibiotics in blood cancer patients (2022, May 12) retrieved 6 May 2024 from https://medicalxpress.com/news/2022-05-arthritis-drug-limit-antibiotics-blood.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.